Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:ASCEND: acalabrutinib vs idelalisib plus rituximab or BRACE-CL-001: acalabrutinib long-term efficacyCLL14: Venetoclax plus obinutuzumabCLARITY: Ibrutinib plus venetoclaxMeasurable residual disease (MRD)Complex karyotypesZanubrutinib plus obinutuzumab and venetoclaxPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.